Pulse Biosciences, Inc

Greetings and welcome to Pulse Bioscience third quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Philip Taylor. Thank you. You may begin.

Thank you, operator. Before we begin, I would like to inform you that comments and responses to your questions during today's call reflect management's views as of today, November 10, 2022 only, and will include forward-looking statements and opinion statements, including predictions, estimates, plans, expectations, and other information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in our filings with the Securities and Exchange Commission. Our SEC filings can be found on our website or on the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements. We will also discuss certain non-GAAP financial measures. Disclosures regarding these non-GAAP financial measures including reconciliations with the most comparable gap measures, can be found in the press release. Please note that this conference call will be available for audio replay on our website at PulseBiosciences.com on the news and events section of our investor relations page. With that, I would now like to turn the call over to President and Chief Executive Officer Kevin Danahy.

Thank you, Tripp. Good afternoon, everyone, and thank you for joining us. On today's call, I will discuss our refreshed vision for the company, including our strategic shift in focus to advance our core MPS technology controlled by the CellFX system in specific sectors of healthcare. I will also highlight the recent changes we made to the organization to support this new strategic direction. And I will turn the call over to our new Chief Technical Officer, Darren Uecker, to discuss our product initiatives. Then Sandy will cover the financial results and we will open the call to questions. To start, I am very excited to lead the company through this next exciting chapter. In present time, the vast majority of our focus is centered on evaluating opportunities in cardiac healthcare where we are confident we can create significant value with our nanopulse field technology. Pulse Bioscience is positioned to make this decisive strategic shift. The preclinical work that we have already completed provides mounting evidence MPS, driven by our novel proprietary Celefex system, can be safe and effective in cardiac tissue ablation. We made the decision to move forward with the use of MPS, controlled by Celefex, in cardiac tissue ablation for the treatment for atrial fibrillation as our lead application. Atrial fibrillation, or AF, is a type of arrhythmia or irregular heartbeat caused by faulty electrical signals in the heart. AF is a highly prevalent condition and is growing significantly with an aging population. It is estimated that 35 million people worldwide are affected by AF. The treatment of AF is performed in hospitals in both the in- and outpatient procedures. Treatment requires the precise and safe ablation of heart tissue to block or otherwise prevent these faulty electrical signals from causing the irregular heartbeat. We believe MPS controlled by CellFX is suited to perform an integral role for this application. Darren will provide more detail on the novel and proprietary mechanism of MPS and why we believe the application of MPS controlled by CellFX in AF can result in a highly differentiated solution of significant value to patients, physicians, cardiac centers, and pulse bioscience stakeholders. As an update on dermatology, we have taken steps to significantly reduce our footprint by reducing the related sales, marketing, and support staff. Now, I'd like to turn it over to Darren.